Resistance in Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 March 2027 | Viewed by 47
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for nearly 25% of all cancer deaths. Despite significant advances in targeted therapies and immunotherapies, the emergence of drug resistance continues to be a major clinical challenge, often resulting in disease relapse and poor outcomes. Both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) exhibit diverse mechanisms of therapeutic resistance, ranging from genetic and epigenetic alterations to tumor–microenvironment interactions and adaptive cellular plasticity.
The prognosis for patients with drug-resistant lung cancer depends largely on the underlying molecular mechanisms. Resistance may arise from secondary mutations (e.g., EGFR T790M, KRAS, and ALK mutations), the activation of bypass signaling pathways (such as MET or HER2), phenotypic changes, including epithelial–mesenchymal transition (EMT) and neuroendocrine transformation, or from extrinsic factors like immune evasion and stromal support. These adaptive responses diminish the efficacy of even the most potent therapies, underscoring the need for innovative treatment strategies.
Recent studies highlight novel approaches with which to overcome resistance, including next-generation targeted therapies, combination regimens, antibody–drug conjugates, and rationally designed immunotherapy strategies. While encouraging, these advances are still insufficient to establish comprehensive, long-term clinical guidelines.
In this context, we aim to explore the epidemiology, resistance mechanisms, tumor microenvironment, and emerging therapeutic strategies in drug-resistant lung cancer in this Special Issue. By keeping the scope broad, we welcome contributions that span basic mechanistic research, translational insights, and clinical perspectives, with particular emphasis on new directions and future opportunities to overcome resistance.
Dr. Mohamed Gadelkarim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- SCLC
- NSCLC
- drug resistance
- genetic mutations
- tumor microenvironment
- EMT
- biomarkers
- targeted therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
